Aluminum foil for cold forming of freeze-dried pharmaceuticals is critical for packaging biological agents and antibiotics. It must meet three non-negotiable performance standards.
First, repeated bending toughness: It needs to withstand ≥50 cycles (embutición taam, plegable, sealing) without cracks. Second, impurity safety: Heavy metals must comply with Guidelines for Compatibility of Pharmaceutical Packaging Materials and Drugs. Third, barrier performance: Oxygen transmission ≤0.1cm³/(m²·24h·atm) and water vapor transmission ≤0.1g/(m²·24h) to protect drugs.
To address these needs, 8079 aleación (Al - Mn, Mn 0.8%-1.2%) is preferred. Its low yield strength (≤110MPa) and high elongation (≥30%) match cold forming demands for pharmaceutical packaging.
Chéen ba'ale', 28% of brittle fractures come from two issues: excessive silicon (>0.15%) y uncontrolled melting impurities (Fe, Cu, Mg forming brittle phases).
For instance, 2024 data shows a pharmacy had 12% rejected freeze-dried vaccine packaging. The cause was 8079 foil brittle fracture during cold forming, leading to an 8 million yuan single-batch loss.
Thus, clarifying why silicon must be ≤0.15% and building a melting impurity control system are urgent to ensure foil reliability.
Fundamentally, the foil’s bending performance (GB leti' t'aano' 31985-2015: ≥50 180° cycles) depends on “dislocation slip ability,” which silicon directly impacts.
Silicon has dual effects: it strengthens via solid solution but can cause embrittlement. Pure aluminum dissolves up to 1.65% silicon at 25℃, but Mn in 8079 alloy reduces this solubility.
Specifically, when Si >0.15%, excess silicon reacts with Al and Fe to form β-AlFeSi brittle phases (1-3μm, HV 280-320). These rigid structures break the matrix’s ductility.
β-AlFeSi phases are acicular or flaky. When distributed at grain boundaries, they act as “micro-cracks” that disrupt continuity.
During bending, stress concentrates at phase tips. Je'ebix., Si=0.2% hinders dislocation slip: elongation drops from 32% Utia'al 22%, and bending cycles fall from 55 Utia'al 28 (Table 1).
As a result, it fails to meet the strict requirements of aluminum foil for cold forming of freeze-dried pharmaceuticals.
To quantify silicon’s impact, a controlled experiment was designed.
Test samples were 0.08mm-thick 8079 foil for cold-formed pharmaceutical trays. Other elements (Fe ≤0.5%, Cu ≤0.1%, Mg ≤0.05%) were fixed; only silicon was adjusted.
Mechanical properties and bending life were tested via standard methods. After tests, results are summarized in Table 1:
1: Only Si ≤0.15% ensures ≥50 bending cycles, meeting cold forming needs.
2: Si ≤0.15% limits brittle fracture rate to ≤3%, critical for high production yields.
3: Si ≤0.15% keeps β-AlFeSi phases ≤2.1%, preserving matrix ductility.
All thresholds meet the demands of aluminum foil for cold forming of freeze-dried pharmaceuticals.
The foil’s melting has two goals: stable Si ≤0.15% and total impurities (Fe+Cu+Mg+Zn) ≤0.7% (no coarse brittle phases).
The process has four sequential stages, each building on the last. Below is a detailed breakdown:
Preventing contamination at the source is more effective than removing it later. Thus, raw material management is key.
High-purity aluminum ingots: Use ≥99.85% purity (Si ≤0.10%, Fe ≤0.15%) to align with pharmaceutical standards.
Recycled aluminum must be avoided. Its Si (0.3%-0.5%) far exceeds limits, making post-melting purification hard.
Beey xan, precise Mn agent proportioning: Use Al-Mn master alloy (Mn 10%-15%, Si ≤0.08%) to adjust Mn content.
For 1.0% target Mn, add 10kg master alloy per 100kg pure aluminum. This avoids excessive Mn reacting with silicon to form brittle phases.
Equally, auxiliary material purification: Melting covering agent (Na₃AlF₆-K₃AlF₆, 560-580℃ melting point) must be dried at 120℃ for 4h.
This removes adsorbed SiO₂, preventing excessive silicon in aluminum foil for cold forming of freeze-dried pharmaceuticals.
Once raw material pretreatment is complete, melting begins—temperature control is key to preventing silicon from furnace linings.
Furnace linings are high-alumina bricks (含 SiO₂), which dissolve into the melt above 720℃, increasing silicon sharply.
To prevent this, jump'éel “stepwise heating” regime is used. Detailed parameters are in Table 2:
Charging stage: 450-500℃ for 30-40min softens ingots slowly, reducing air and impurities.
Low-temperature melting: 680-720℃ for 60-80min is critical. Above 720℃, SiO₂ dissolution spikes, causing irreversible silicon overload.
Composition adjustment: 730-750℃ for 20-30min ensures uniform Mn dissolution. Overheating here accelerates silicon migration.
Standing stage: 720-730℃ for 15-20min reduces convection, avoiding uneven silicon (brittle in some areas, ductile in others).
Adicionalmente, real-time silicon monitoring: Take samples every 30min, test via direct-reading spectrometer (0.001% accuracy).
If Si nears 0.14%, add pure aluminum (Si ≤0.10%) to dilute. This keeps final Si of aluminum foil for cold forming of freeze-dried pharmaceuticals at 0.12%-0.15%.
Following temperature control, refining removes residual silicon and impurities that cause brittle fractures.
First, gas refining: Use N₂-Cl₂ mixed gas (9:1, ≥99.999% purity). Insert a graphite nozzle 150-200mm deep into the melt.
Flow rate: 0.5-0.8m³/(t·min); duration:15-20min. Nitrogen removes hydrogen (≤0.15mL/100gAl), avoiding porosity in the final foil.
Chlorine reacts with Fe/Cu to form volatile FeCl₃/CuCl₂, reducing Fe from 0.3% Utia'al 0.18% and Cu from 0.08% Utia'al 0.03%.
This avoids impurity-induced bending toughness loss.
Second, flux refining: After gas refining, add 2%-3% Na₂CO₃-K₂CO₃ flux (1:1 mass ratio) to target residual silicides.
Stir for 10min, then stand for 20min. Flux reacts with silicides to form Na₂SiO₃, which floats with slag and is removed.
This further reduces Si by 0.02%-0.03%, moving it closer to 0.12%-0.15%.
Third, filtration purification: With chemical refining done, pass the melt through double-layer ceramic filters (upper 50μm, lower 20μm).
Control flow rate at 0.5-0.8m/min to avoid turbulence. Filters remove ≥20μm β-AlFeSi phases with ≥95% efficiency.
This ensures microstructural uniformity critical for aluminum foil for cold forming of freeze-dried pharmaceuticals.
With refining finished, casting and homogenization optimize the ingot’s microstructure for rolling, ensuring ductility.
Semi-continuous casting: Control parameters for fine grains (key for bending performance).
Casting temperature:710-720℃ (fluid enough to fill molds, no grain coarsening). Mold water temperature:25-30℃ (uniform cooling).
Cooling intensity:1500-2000W/(m²·K) (rapid solidification for fine grains). Casting speed:60-80mm/min (balances efficiency and quality).
These parameters yield ingots with 50-80μm grains. Fine grains reduce brittle phase concentration at boundaries, enhancing toughness.
Homogenization treatment: Heat cast ingots at 580-600℃ for 8-10h (below melting point, drives phase changes).
Cool with the furnace to 300℃ (avoid thermal shock), then air-cool to room temperature.
This converts residual β-AlFeSi to more stable α-AlFeSi (HV 220-240, better toughness). Elongation increases by 3%-5%, meeting pharmaceutical cold forming needs.
To fully validate the optimized melting process, rigorous laboratory tests were conducted.
Test samples:0.08mm-thick 8079 florete, specifically aluminum foil for cold forming of freeze-dried pharmaceuticals made via the above process.
Tests covered six metrics: Si content, Fe impurities, alargamiento, bending cycles, brittle fracture rate, and oxygen transmission. All followed standards like YBB00152002-2015.
Results are in Table 3, confirming compliance with pharmaceutical requirements:
1: Si=0.13% (within ≤0.15%), confirming stable control.
2: Elongation=30.5% (>28%), leading to 56 bending cycles (60% more than pre-optimization).
3: Brittle fracture rate=2.1% (<5%), ensuring high production yields.
4: Oxygen transmission=0.08cm³/(m²·24h·atm) (<0.1%), protecting drugs from oxidation.
For real-world impact, consider a major vaccine enterprise that faced 2023 production issues.
Background: The enterprise used 8079 foil with Si=0.19% for vaccine packaging.
During cold forming, brittle fracture rate reached 11.2%, rejecting 500,000+ packages and causing delays.
Faced with this issue, the enterprise incurred high rework costs and missed deadlines, needing urgent upgrades.
Process adjustments: To fix this, it adopted the optimized process to make aluminum foil for cold forming of freeze-dried pharmaceuticals.
First, replace low-purity ingots with 99.85% pure ones (reduced initial silicon).
Second, use 720℃ low-temperature melting (prevented silicon from linings).
Third, implement N₂-Cl₂ refining (reduced Fe/Cu to non-brittle levels).
These adjustments stabilized final Si at 0.12%-0.14%.
Performance effects: As a direct result, bending cycles rose from 32 Utia'al 55 (meeting ≥50).
Brittle fracture rate dropped from 11.2% Utia'al 1.8%, cutting costs and eliminating delays.
Financially, annual losses fell by 6 million yuan, recovering upgrade costs in 6 months.
Compliance validation: The enterprise submitted the foil for regulatory inspection.
Ya'ala'al: Heavy metals (Pb ≤0.001%, Cd ≤0.0005%) met standards. It complied with YBB00152002-2015.
Vaccine compatibility tests showed no harmful leaching, ensuring patient safety.
These results confirmed it met aluminum foil for cold forming of freeze-dried pharmaceuticals requirements.
Summarizing the key findings: 8079 aleación ju'un aluminio for cold forming of freeze-dried pharmaceuticals must have Si ≤0.15%.
Wa >0.15% forms β-AlFeSi brittle phases, reducing elongation and bending life—making it unsuitable for cold forming.
Via the integrated process (“high-purity raw materials – low-temperature melting – composite refining – fine-grained casting”), three goals are met:
Looking ahead, three innovations will improve performance, sostenibilidad, and applicability:
First, intelligent melting systems: Integrate AI visual recognition and real-time spectral analysis.
AI monitors slag silicon in real time; spectral analysis adjusts Si by adding pure aluminum automatically.
This closed-loop control reduces human error, improving foil quality stability.
Second, green refining: Replace chlorine with eco-friendly agents (p'el ej., Al₂O₃-CaO-MgO).
These remove Fe/Cu without toxic chlorine, aligning with pharmaceutical green production trends.
Third, alloy micro-alloying: Add 0.02%-0.03% Ti to refine grains to 30-50μm (smaller than current 50-80μm).
Finer grains enhance toughness and barriers, expanding use to ultra-thin foils (p'el ej., single-dose drug packaging).
Above all, the melting process must “prioritize pharmaceutical safety and formability” at every step.
Only with precise silicon/impurity control and ductile microstructure optimization can freeze-dried drug stability be guaranteed.
This guarantee extends across the drug lifecycle (embalaje, transporte, almacenamiento, use).
This principle remains the core technical standard for producing aluminum foil for cold forming of freeze-dried pharmaceuticals and will guide future innovations.
